In preclinical models, it had been shown before that dual GLP-1/GCG as well as dual GLP-1/GIP agonists improve metabolic parameters and are capable of fighting obesity [97,98]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.